Biosketch Ana Vivancos

Biosketch Ana Vivancos
Ana Vivancos
avivancos@vhio.net
Current position

Group Leader of VHIO´s Cancer Genomics Group

Honors and Memberships

Reviewer for: Clinical Cancer Research, Nature, and Oncogene.

Academic Qualifications
  • PhD, Biochemistry and Molecular Biology, Universitat Pompeu Fabra, 2006. Dissertation: Role of the peroxiredoxin Tpx1 and the transcription factor Pap1 in the response to H2O2 in Schizosaccharomyces pombe.
  • B.A, Biochemistry, Universitat de Barcelona, 2000.
Prizes and Scholarships
  • Juan de la Cierva Post-doctoral Contract (Ministerio de Educación y Ciencia), 2007.
  • Pre-doctoral FPI (Formación de Personal Investigador) Grant (Ministerio de Ciencia y Tecnología).
Projects
  1. Avanzando hacia la implementación clínica: Estudio de las bases moleculares de la liberación de DNA tumoral en sangre. FIS-ISCIII.  (PI20/01112). PI: Ana Vivancos. 01/01/2021 – 31/12/2023.
  2. A pivotal study of derazantinib in patients with inoperable or advanced intrahepatic cholangiocarcinoma and FGFR2 gene fusions or FGFR2 gene mutations or amplifications. PI: Ana Vivancos. 22/02/2021 – 31/12/2021.
  3. ctDNA in breast milk for early detection of pregnancy associated breast cancer. FERO Foundation. PI: Miriam Sansó. 01/07/2020 – 30/06/2022.
  4. Tumores primarios múltiples en pacientes con cáncer de pulmón: elaboración de un perfil molecular integral para elucidar orígenes genéticos comunes. Fundación Científica de la Asociación Española Contra el Cáncer (AECC). PI: Miriam Sansó. 01/12/2019 – 30/11/2023.
  5. Phase II Study of Avelumab plus chemotherapy in the peri-operative treatment for patients with resectable Gastric cancer (GC) or Gastroesophageal Junction cancer (GECJ). Merck Healthcare KGaA. PI: Ana Vivancos. 10/04/2019 – 31/12/2026.
  6. CeLac and European consortium for a personalized medicine approach to Gastric Cancer-LEGACy. European Commission-LEGACy. PI: Ana Vivancos. 01/01/2019-31/12/2022.
  7. Estudio de la microbiota, de Fusobacterium nucleatum y de la correlación con las vías de los receptores de Toll-like en tumores neuroendocrinos de intestino delgado. PI: Ana Vivancos. 21/07/2021 -3 1/12/2022.
  8. Olaparib and durvalumab (MEDI4736) in patients with metastatic pancreatic cancer and DNA Damage Repair genes alterations. PI: Ana Vivancos. 27/10/2021-31/12/2022.
Most relevant scientific publications
  • Frigola J, Navarro A, Carbonell C, Callejo A, Iranzo P, Cedrés S, Martinez-Marti A, Pardo N, Saoudi-Gonzalez N, Martinez D, Jimenez J, Sansano I, Mancuso FM, Nuciforo P, Montuenga LM, Sánchez-Cespedes M, Prat A, Vivancos A, Felip E, Amat R. Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer. Mol Oncol. 2021 Apr;15(4):887-900.
  • Kagawa Y, Elez E, García-Foncillas J, Bando H, Taniguchi H, Vivancos A, Akagi K, García A, Denda T, Ros J, Nishina T, Baraibar I, Komatsu Y, Ciardiello D, Oki E, Kudo T, Kato T, Yamanaka T, Tabernero J, Yoshino T. Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for RAS Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM Study. Clin Cancer Res. 2021 May 1;27(9):2515-2522.
  • Ogbah Z, Mancuso FM, Vivancos A. MYC Copy Number Detection in Clinical Samples Using a Digital DNA-Hybridization and Detection Method. Methods Mol Biol. 2021;2318:321-336.
  • Brasó-Maristany F, Sansó M, Chic N, Martínez D, González-Farré B, Sanfeliu E, Ghiglione L, Carcelero E, Garcia-Corbacho J, Sánchez M, Soy D, Jares P, Peg V, Saura C, Muñoz M, Prat A, Vivancos A. Case Report: A Case Study Documenting the Activity of Atezolizumab in a PD-L1-Negative Triple-Negative Breast Cancer. Front Oncol. 2021 Sep 20;11:710596.
  • Capdevila J, Mayor R, Mancuso FM, Iglesias C, Caratú G, Matos I, Zafón C, Hernando J, Petit A, Nuciforo P, Cameselle-Teijeiro JM, Álvarez CV, Recio JA, Tabernero J, Matias-Guiu X, Vivancos A, Seoane J. Early evolutionary divergence between papillary and anaplastic thyroid cancers. Ann Oncol. 2019 Nov 1;30(11):1843.
  • Elez E, Chianese C, Sanz-García E, Martinelli E, Noguerido A, Mancuso FM, Caratù G, Matito J, Grasselli J, Cardone C, Esposito Abate R, Martini G, Santos C, Macarulla T, Argilés G, Capdevila J, Garcia A, Mulet N, Maiello E, Normanno N, Jones F, Tabernero J, Ciardello F, Salazar R, Vivancos A. Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS-mutant metastatic colorectal cancer. Mol Oncol. 2019 Sep;13(9):1827-1835.
  • Vivancos A, Aranda E, Benavides M, Élez E, Gómez-España MA, Toledano M, Alvarez M, Parrado MRC, García-Barberán V, Diaz-Rubio E. Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples. Sci Rep. 2019 Jun 20;9(1):8976.
  • Rodriguez-Freixinos V, Ruiz-Pace F, Fariñas-Madrid L, Garrido-Castro AC, Villacampa G, Nuciforo P, Vivancos A, Dienstmann R, Oaknin A. Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer. ESMO Open. 2019 Mar 8;4(2):e000444.
  • Arqués O, Chicote I, Puig I, Tenbaum SP, Argilés G, Dienstmann R, Fernández N, Caratù G, Matito J, Silberschmidt D, Rodon J, Landolfi S, Prat A, Espín E, Charco R, Nuciforo P, Vivancos A, Shao W, Tabernero J, Palmer HG. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. Clin Cancer Res. 2016 Feb 1;22(3):644-56.
  • Vivancos A, Caratú G, Matito J, Muñoz E, Ferrer B, Hernández-Losa J, Bodet D, Pérez-Alea M, Cortés J, Garcia-Patos V, Recio JA. Genetic evolution of nevus of Ota reveals clonal heterogeneity acquiring BAP1 and TP53 mutations. Pigment Cell Melanoma Res. 2016 Mar;29(2):247-53.
  • Pérez-Alea M, Vivancos A, Caratú G, Matito J, Ferrer B, Hernandez-Losa J, Cortés J, Muñoz E, Garcia-Patos V, Recio JA. Genetic profile of GNAQ-mutated blue melanocytic neoplasms reveals mutations in genes linked to genomic instability and the PI3K pathway. Oncotarget. 2016 May 10;7(19):28086-95.
  • Yus E, Güell M, Vivancos AP, Chen WH, Lluch-Senar M, Delgado J, Gavin AC, Bork P, Serrano L. Transcription start site associated RNAs in bacteria. Mol. Syst. Biol. 2012; 8: 585
  • Esteve-Codina A, Kofler R, Himmelbauer H, Ferretti L, Vivancos AP, Groenen MA, Folch JM, Rodríguez MC, Pérez-Enciso M. Partial short-read sequencing of a highly inbred Iberian pig and genomics inference thereof. Heredity (Edinb) 2011 Sep; 107(3): 256-64
  • Zuin A, Carmona M, Morales-Ivorra I, Gabrielli N, Vivancos AP, Ayté J, Hidalgo E. Lifespan extension by calorie restriction relies on the Sty1 MAP kinase stress pathway. EMBO J. 2010 Mar; 29(5): 981-91
  • Vivancos AP, Castillo EA, Biteau B, Nicot C, Ayté J, Toledano MB, Hidalgo E. A cysteine-sulfinic acid in peroxiredoxin regulates H2O2-sensing by the antioxidant Pap1 pathway. Proc. Natl. Acad. Sci. U.S.A. 2005 Jun; 102(25): 8875-80
  • Vivancos AP, Castillo EA, Jones N, Ayté J, Hidalgo E. Activation of the redox sensor Pap1 by hydrogen peroxide requires modulation of the intracellular oxidant concentration. Mol. Microbiol. 2004 Jun; 52(5): 1427-35
  • Castillo EA, Vivancos AP, Jones N, Ayté J, Hidalgo E. Schizosaccharomyces pombe cells lacking the Ran-binding protein Hba1 show a multidrug resistance phenotype due to constitutive nuclear accumulation of Pap1. J. Biol. Chem. 2003 Oct; 278(42): 40565-72
All publications
  • Pérez-Alea M, Vivancos A, Caratú G, Matito J, Ferrer B, Hernandez-Losa J, Cortés J, Muñoz E, Garcia-Patos V, Recio JA. Genetic profile of GNAQ-mutated blue melanocytic neoplasms reveals mutations in genes linked to genomic instability and the PI3K pathway. Oncotarget. 2016 May 10;7(19):28086-95. doi: 10.18632/oncotarget.8578.
  • Arqués O, Chicote I, Puig I, Tenbaum SP, Argilés G, Dienstmann R, Fernández N, Caratù G, Matito J, Silberschmidt D, Rodon J, Landolfi S, Prat A, Espín E, Charco R, Nuciforo P, Vivancos A, Shao W, Tabernero J, Palmer HG. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. Clin Cancer Res. 2016 Feb 1;22(3):644-56. doi: 10.1158/1078-0432.CCR-14-3081.
  • Ibarrola-Villava M, Fleitas T, Llorca-Cardeñosa MJ, Mongort C, Alonso E, Navarro S, Burgues O, Vivancos A, Cejalvo JM, Perez-Fidalgo JA, Roselló S, Ribas G, Cervantes A. Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology. Oncotarget. 2016 Apr 19;7(16):22543-55. doi: 10.18632/oncotarget.8002.
  • Alves-Rodrigues I, Ferreira PG, Moldón A, Vivancos AP, Hidalgo E, Guigó R, Ayté J. Spatiotemporal Control of Forkhead Binding to DNA Regulates the Meiotic Gene Expression Program. Cell Rep. 2016 Feb 2;14(4):885-95. doi: 10.1016/j.celrep.2015.12.074.
  • Vivancos A, Caratú G, Matito J, Muñoz E, Ferrer B, Hernández-Losa J, Bodet D, Pérez-Alea M, Cortés J, Garcia-Patos V, Recio JA. Genetic evolution of nevus of Ota reveals clonal heterogeneity acquiring BAP1 and TP53 mutations. Pigment Cell Melanoma Res. 2016 Mar;29(2):247-53. doi: 10.1111/pcmr.12452.
  • Yus E, Güell M, Vivancos AP, Chen WH, Lluch-Senar M, Delgado J, Gavin AC, Bork P, Serrano L. Transcription start site associated RNAs in bacteria. Mol. Syst. Biol. 2012; 8: 585
  • Esteve-Codina A, Kofler R, Himmelbauer H, Ferretti L, Vivancos AP, Groenen MA, Folch JM, Rodríguez MC, Pérez-Enciso M. Partial short-read sequencing of a highly inbred Iberian pig and genomics inference thereof. Heredity (Edinb) 2011 Sep; 107(3): 256-64
  • Zuin A, Carmona M, Morales-Ivorra I, Gabrielli N, Vivancos AP, Ayté J, Hidalgo E. Lifespan extension by calorie restriction relies on the Sty1 MAP kinase stress pathway. EMBO J. 2010 Mar; 29(5): 981-91
  • Vivancos AP, Castillo EA, Biteau B, Nicot C, Ayté J, Toledano MB, Hidalgo E. A cysteine-sulfinic acid in peroxiredoxin regulates H2O2-sensing by the antioxidant Pap1 pathway. Proc. Natl. Acad. Sci. U.S.A. 2005 Jun; 102(25): 8875-80
  • Vivancos AP, Castillo EA, Jones N, Ayté J, Hidalgo E. Activation of the redox sensor Pap1 by hydrogen peroxide requires modulation of the intracellular oxidant concentration. Mol. Microbiol. 2004 Jun; 52(5): 1427-35
  • Castillo EA, Vivancos AP, Jones N, Ayté J, Hidalgo E. Schizosaccharomyces pombe cells lacking the Ran-binding protein Hba1 show a multidrug resistance phenotype due to constitutive nuclear accumulation of Pap1. J. Biol. Chem. 2003 Oct; 278(42): 40565-72
Privacy Preferences
When you visit our website, it may store information through your browser from specific services, usually in form of cookies. Here you can change your privacy preferences. Please note that blocking some types of cookies may impact your experience on our website and the services we offer.
Privacy Policy
You have read and agreed to our privacy policy
Required